Carboplatin re-treatment in platinum-resistant epithelial ovarian cancer patients.

Mads Kingo Guldberg HansenMaja Patricia SmerdelMarianne WaldstrømRikke Fredslund AndersenParvin AdimiAnders JakobsenKarina Dahl Steffensen

Published in: Cancer chemotherapy and pharmacology (2020)

Our results might provide guidance in cases with heavily pre-treated patients, where alternatives are limited. Carboplatin and bevacizumab treatment should be weighed against best supportive care, current non-platinum therapies and experimental treatment. cfDNA seems to offer prognostic insight.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
peritoneal dialysis
prognostic factors
randomized controlled trial
quality improvement
pain management
chronic pain
smoking cessation
affordable care act